Last reviewed · How we verify
NCT03882580: NEOCARDIO
Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care
trial testing Anti-Cancer Agents in Cardiovascular Complication in 5,000 participants. Status unknown.
1 March 2025
Quick facts
| Lead sponsor | Groupe Hospitalier Pitie-Salpetriere |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 5,000 |
| Start date | 1 March 2019 |
| Primary completion | 1 March 2025 |
| Estimated completion | 1 March 2025 |
| Sites | 3 locations across France |
Drugs / interventions tested
- Anti-Cancer Agents — full drug profile →
Conditions studied
- Cardiovascular Complication — all drugs for Cardiovascular Complication →
- Cardiovascular Insufficiency — all drugs for Cardiovascular Insufficiency →
- Cardiac Complication — all drugs for Cardiac Complication →
- Oncologic Complications — all drugs for Oncologic Complications →
Sponsor
Groupe Hospitalier Pitie-Salpetriere
Who can join
18 and older, any sex, with Cardiovascular Complication or Cardiovascular Insufficiency. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Several Drugs used in routine care in oncology induce rare but often severe or fatal cardiovascular or metabolic side effects. This study will investigate, evaluate, report and treat the cardiovascular side effects of anticancer drugs, through a specific cardiovascular routine checkup and follow-up taking place in several Cardio-oncology programs throughout France. The different including centers will be: Assistance Publique - Hôpitaux de Paris (APHP.6: Pitié-Salpétrière, Saint Antoine and Tenon's hospitals, Paris, France).
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors.
Dolladille C, Ederhy S, Allouche S, Dupas Q, et al · · 2020 · cited 66× · PMID 31988143 · DOI 10.1136/jitc-2019-000261 -
VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications.
Camarda N, Travers R, Yang VK, London C, et al · · 2022 · cited 49× · PMID 35179707 · DOI 10.1007/s11912-022-01224-0 -
Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension-Mechanisms and Mitigation.
Butel-Simoes LE, Haw TJ, Williams T, Sritharan S, et al · · 2023 · cited 13× · PMID 36756872 · DOI 10.1161/hypertensionaha.122.17947 -
Validation of a novel semi-automated ECG quantification tool, applied to a cardio-oncology : Semi-automated ECG Tool applied to cardio-oncology.
Cohen SD, Robert-Halabi M, Procureur A, Jamelot M, et al · · 2025 · PMID 41419945 · DOI 10.1186/s40959-025-00405-7
Verify or expand the search:
- PubMed search for NCT03882580
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiovascular Complication
Currently open trials in the same condition.
- NCT06279000 — Colchicine in Patients at Cardiac Risk Undergoing Major Non-Cardiac Surgery · Phase 3 · recruiting
- NCT06902857 — Study on the Predictive Value of High-sensitivity Cardiac Troponin I, N-terminal Pro-B-natriuretic Peptide, and Soluble · recruiting
- NCT06358079 — Re-infusion of Unwashed Shed Blood During Off-pump Surgery · NA · active not recruiting
- NCT06826534 — At-Home Cardiac Rehabilitation for Adolescents at Risk for Heart Failure · NA · recruiting
- NCT05679024 — Stroke Prophylaxis With Apixaban in Chronic Kidney Disease Stage 5 Patients With Atrial Fibrillation · Phase 3 · recruiting
Other Groupe Hospitalier Pitie-Salpetriere trials
Trials by the same sponsor.
- NCT06515678 — Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension · active not recruiting
- NCT05934214 — EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Databa · completed
- NCT05819736 — Pharmacokinetics Study Of Rivaroxaban and Apixaban in Cancer Patients · unknown
- NCT04320017 — Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observa · completed
- NCT04314817 — Adverse Events Related to Treatments Used Against Coronavirus Disease 2019 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03882580 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Groupe Hospitalier Pitie-Salpetriere
- Last refreshed: 24 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03882580.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing